Aneuploid Cell Survival Relies upon Sphingolipid Homeostasis

• Main Authors: Tang, Yun-Chi (Author), Yuwen, Hui (Author), Wang, Kaiying (Author), Bruno, Peter M. (Author), Bullock, Kevin (Author), Deik, Amy (Author), Zhong, Na (Author), Huang, Tao (Author), Wang, Lan (Author), Clish, Clary B. (Author), Hemann, Michael T. (Author), Santaguida, Stefano (Contributor), Trakala, Marianna (Contributor), Pfau, Sarah Jeanne (Contributor), Amon, Angelika B (Contributor)
• Other Authors: Massachusetts Institute of Technology. Department of Biology (Contributor), Koch Institute for Integrative Cancer Research at MIT (Contributor)
• Format: Article
• Language: English
• Published: American Association for Cancer Research (AACR), 2018-10-31T19:27:03Z.
• Subjects: Article
• Online Access: Get fulltext

 Aneuploidy, a hallmark of cancer cells, poses an appealing opportunity for cancer treatment and prevention strategies. Using a cell-based screen to identify small molecules that could selectively kill aneuploid cells, we identified the compound N-[2hydroxy-1-(4-morpholinylmethyl)-2-phenylethyl]-decanamide monohydrochloride (DL-PDMP), an antagonist of UDP-glucose ceramide glucosyltransferase. DL-PDMP selectively inhibited proliferation of aneuploid primary mouse embryonic fibroblasts and aneuploid colorectal cancer cells. Its selective cytotoxic effects were based on further accentuating the elevated levels of ceramide, which characterize aneuploid cells, leading to increased apoptosis. We observed that DL-PDMP could also enhance the cytotoxic effects of paclitaxel, a standard-of-care chemotherapeutic agent that causes aneuploidy, in human colon cancer and mouse lymphoma cells. Our results offer pharmacologic evidence that the aneuploid state in cancer cells can be targeted selectively for therapeutic purposes, or for reducing the toxicity of taxane-based drug regimens.